Drug Trial Radar · NCT04053803
An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia
Last checked: Nov 20, 2026Latest source record: Mar 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
May 22, 2019
Primary completion
Mar 2025
Study completion Mar 2025
Sponsor
- Lead sponsor
- Imara, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 13, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label extension study of IMR-687 in adult patients who completed Imara's blinded Phase 2a study (IMR-SCD-102). The open-label extension study will evaluate long-term safety and tolerability.
Conditions
- Sickle Cell Disease
Interventions
IMR-687Drug
Oral administration of once daily IMR-687
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with adverse events and serious adverse eventsTime frame: Baseline to Month 49
- Proportion of patients with changes in safety cardiac parametersTime frame: Baseline to Month 49
- Proportion of patients with changes in clinical laboratory testsTime frame: Baseline to Month 49
- Proportion of patients with clinically significant abnormal vital signsTime frame: Baseline to Month 49
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
University of Connecticut Health Center
Farmington, Connecticut
Foundation for Sickle Cell Disease Research
Hollywood, Florida
Baylor Scott & White Medical Center - Temple
Temple, Texas
Bristol Haematology and Oncology Centre
Bristol, United Kingdom
University College London Hospital NHS Foundation Trust
London, United Kingdom
Guy's and St Thomas Hospital CRF
London, United Kingdom
Royal London Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.